Cancer Treatment Reviews
Volume 26, Issue 1 , Pages 53-65 , February 2000

Bone marrow and lymph node assessment for minimal residual disease in patients with breast cancer

  • I.J. Diel

      Affiliations

    • Department of Ob/Gyn, University of Heidelberg, Germany
    • ,
  • R.J. Cote

      Affiliations

    • USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, USA

References 

    REFERENCES
  1. Asworth TR. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J. 1869;14:146
  2. Engell HC. Cancer cells in the circulating blood. Acta Chir Scand. 1955;Suppl
  3. Christopherson W. Cancer cells in the peripheral blood: a second look. Acta Cytol. 1965;9:169–174
  4. Ingle JN, Tormey DC, Tan HK. The bone marrow examination in breast cancer. Cancer. 1978;41:670–674
  5. Landys KE. Prognostic value of bone marrow biopsies in breast cancer. Cancer. 1982;49:513–518
  6. Diel IJ, Krempien B, Kaufmann M, Costa SD, Goerner R, von Fournier D, et al. Ergebnisse von Beckenkammbiopsien von 475 Patientinnen mit primärem und metastasiertem Mammakarzinom. Tumordiagn u Ther. 1992;13:85–90
  7. Frey U, Senn HJ. Nachweis ossärer Tumormikrometastasen: Vergleich der Aussagekraft von Knochenmarkszytologie und -histologie. Schweiz Med Wschr. 1978;108:82
  8. Sloane JP, Ormerod MC, Neville AM. Potential pathological application of immunocytochemical methods to the detection of micrometastases. Cancer Res. 1980;40:3079–3082
  9. Sloane JP, Ormerod MG, Imrie SF, Coombes RC. The use of antisera to epithelial membrane antigen in detecting micrometastases in histological sections. Br J Cancer. 1980;42:392–398
  10. Sloane JP, Ormerod MG. Distribution of epithelial membrane antigen in normal and neoplastic tissues and its value in diagnostic tumor pathology. Cancer. 1981;47:1786–1795
  11. Dearnaley DP, Sloane JP, Ormerod MG, Steele K, Coombes RC, Clink HMcD, et al. Increased detection of mammary carcinoma cells in marrow smears using antisera to epithelial membrane antigen. Br J Cancer. 1981;44:85–90
  12. Dearnaley DP, Sloane JP, Imrie SF, Coombes RC, Ormerod MG, Lumley H, et al. Detection of isolated mammary carcinoma cells in marrow of patients with primary breast cancer. J Roy Soc Med. 1983;76:359–364
  13. Redding WH, Coombes RC, Monaghan P, Clink HMcD, Imrie SF, Dearnaley DP, et al. Detection of micrometastases in patients with primary breast cancer. Lancet II. 1983;1271–1274
  14. Diel IJ, Kaufmann M, Costa SD, Bastert G. Monoclonal antibodies to detect breast cancer cells. In:  De Vita VT,  Hellman S,  Rosenberg SA editor. Important advances in oncology. Philadelphia: Lippincott; 1994;p. 143–164
  15. Pantel K, Itzbicki J, Angstwurm M, Hönsinger K, Thetter O, Riethmüller G. Frequency and prognostic significance of isolated tumor cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet. 1996;347:649–653
  16. Chaiwun B, Saad A, Groshen S. Immunohistochemical detection of occult carcinoma in bone marrow and blood: Critical analysis of efficiency of separation, preparation, and limits of detection in a model sytem. Diagn Oncol. 1992;2:267–276
  17. Mansi JL, Easton D, Berger U, Gazet JC, Ford HT, Dearnaley DP, et al. Bone marrow micrometastases in primary breast cancer: Prognostic significance after 6 years Follow-up. Eur J Cancer. 1991;27:1552–1555
  18. Diel IJ, Kaufmann M, Solomayer EF, Wallwiener D, Gollan Ch, Goerner R, et al. Prognostische Bedeutung des Tumorzellnachweises im Knochenmark im Vergleich zum Nodalstatus bei 1026 Patientinnen mit primärem Mammakarzinom. Geburtsh u Frauenheilk. 1997;57:333–341
  19. Landys K, Persson S, Kovarik J, Hultborn R, Holmberg E. Prognostic value of bone marrow biopsy in operable breast cancer patients at the time of initial diagnosis: results of a 20-year median follow-up. Breast Cancer Res Treat. 1998;49:27–33
  20. Solomayer EF, Diel IJ, Krempien B, Meyberg GC, Gollan Ch, Krainick U, et al. Results of iliac crest biopsies taken from 1465 patients with primary breast cancer. J Cancer Res Clin Oncol. 1998;124:44–48
  21. Osborne MP, Rosen PP. Detection and management of bone marrow micrometastases in breast cancer. Oncology. 1994;8:25–31
  22. Pelkey TJ, Frierson HF, Bruns DE. Molecular and immunological detection of circulating tumor cells and micrometastases from solid tumors. Clin Chem. 1996;42:1369–1381
  23. Harbeck N, Abdulsalam A, Jänicke F. Clinical relevance of detection of tumor cells in the bone marrow of primary breast cancer patients: A review. Onkologie. 1997;20:387–392
  24. Jauch KW, Friess S, Grützner U, Heiss MM, Funke I. Prognostic significance of micrometastases. Onkologie. 1995;18:525–532
  25. Pantel K, Felber E, Schlimok G. Detection and characterization of residual disease in breast cancer. J Hematother. 1994;3:315–322
  26. Pantel K, Riethmüller G. Methods for Detection of micrometastatic carcinoma cells in bone marrow, blood and lymph nodes. Onkologie. 1995;18:394–401
  27. Braun S, Müller M, Hepp F, Schlimok G, Riethmüller G, Pantel K. Re: Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status (correspondence). J Natl Cancer Inst. 1998;90:1099–1100
  28. Braun S, Pantel K. Prognostic significance of micrometastatic bone marrow involvement. Breast Cancer Res Treat. 1998;52:201–216
  29. Ahr A, Scharl A, Müller M, von Minckwitz G, Gätje R, Pantel K, et al. Cross-reactive staining of normal bone marrow cells by monoclonal antibody 2E11. Int J Cancer. 1999;84:502–505
  30. Brugger W, Bühring HJ, Grünebach F, Vogel W, Müller R, Brümmendorf TH, et al. Expression of MUC-1 epitopes on normal bone marrow: implications for the detection of micrometastatic tumor cells. J Clin Oncol. 1999;17:1535–1544
  31. Schlimok G. Techniken zur Erkennung minimal residueller Erkrankung: Zytologie. Onkologe. 1997;3:293–297
  32. Viglione M, Thor A. Application of monoclonal antibodies for the detection of occult breast carcinoma metastases in bone marrow. Lab Invest. 1987;56:83
  33. Thor A, Viglione MJ, Ohuchi N, Simpson J, Steis R, Cousar J, et al. Comparison of monoclonal antibodies for the detection of occult breast carcinoma metastases in bone marrow. Breast Cancer Res Treat. 1988;11:133–145
  34. Mathieu MC, Friedman S, Bosq J, Caillou B, Spielmann M, Travagli JP, et al. Immunohistochemical staining of bone marrow biopsies for detection of occult metastasis in breast cancer. Breast Cancer Res Treat. 1990;15:21–26
  35. Pantel K, Schlimok G, Angstwurm M, Weckermann D, Schmaus W, Gath H, et al. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. J Hematother. 1994;3:165–173
  36. Osborne MP, Wong GY, Asina S, Old LJ, Cote RJ, Rosen PP. Cancer Res. 1991;51:2706–2709
  37. Schlimok G, Funke I, Holzmann B, Göttlinger G, Schmidt G, Häuser H, et al. Micrometastatic cancer cells in bone marrow: In vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Proc Natl Acad Sci USA. 1987;84:8672–8676
  38. Ellis G, Ferguson M, Yamanaka E, Livingston RB, Gown AM. Monoclonal antibodies for detection of occult carcinoma cells in bone marrow of breast cancer patients. Cancer. 1989;63:2509–2514
  39. Osborne MP, Asina S, Wong GY, Old LJ, Cote RJ. Immunofluorescent monoclonal antibody detection of breast cancer in bone marrow: sensitivity in a model system. Cancer Res. 1989;49:2510–2513
  40. Pantel K, Cote RJ, Fodstad O. Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst. 1999;91:1113–1124
  41. Coombes RC, Dearnaley DP, Buckman R, Jones JM, Ormerod MG, Sloane JP, et al. Detection of bone metastases in patients with breast cancer. Invasion Metastasis. 1982;2:177–184
  42. Coombes RC, Berger U, Mansi J, Redding WH, Powles TJ, Neville AM, et al. Prognostic significance of micrometastases in bone marrow of patients with primary breast cancer. NCI Monogr. 1986;1:51–53
  43. Berger U, Bettelheim R, Mansi JL, Easton D, Coombes RC, Neville AM. The relationship between micrometastases in the bone marrow, histopathological features of the primary tumor in breast cancer and prognosis. Am J Clin Pathol. 1988;90:1–6
  44. Mansi JL, Berger U, Easton D, McDonnell T, Redding WH, Gazet JC, et al. Micrometastases in bone marrow in patients with primary breast cancer: evaluation as an early predictor of bone metastases. Br Med J. 1987;295:1093–1096
  45. Mansi JL, Gogas H, Bliss JM, Gazet JC, Berger U, Coombes RC. Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study. Lancet. 1999;354:197–202
  46. Diel IJ, Kaufmann M, Goerner R, Costa SD, Kaul S, Bastert G. Detection of tumor cells in bone marrow of patients with primary breast cancer: A prognostic factor for distant metastasis. J Clin Oncol. 1992;10:1534–1539
  47. Diel IJ, Kaufmann M, Costa SD, Holle R, von Minckwitz G, Solomayer EF, et al. Micrometastatic breast cancer cells in bone marrow at primary surgery – prognostic value in comparison to nodal status. J Natl Cancer Inst. 1996;88:1652–1658
  48. Funke I. Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated. J Clin Oncol. 1998;16:557–566
  49. Funke IFS, Jauch KW. Tumorzellnachweis im Knochenmark: Entscheidungshilfe zur adjuvanten Therapie bei nodal-negativen Patientinnen mit Mammakarzinom. Chirurg. 1991;62:805–809
  50. Jurcic, J. G. Scheinberg, D. A. Houghton, A. N. Monoclonal antibody therapy of cancer. Cancer Chemotherapy and Biological Response Modifiers Annual 16, Pinedo, H. M.Longo, D. L.Chabner, B. A. 1996, New York, Elsevier, 168, 88
  51. Mansi JL, Berger U, McDonnell T, Pople A, Rayter Z, Coombes RC. The fate of bone marrow micrometastases in patients with primary breast cancer. J Clin Oncol. 1989;7:445–449
  52. Diel IJ, Solomayer EF, Gollan Ch, Costa SD, Kaufmann M, Wallwiener D, et al. Prognostic impact of minimal residual disease in breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat. 1997;46/1:Abstr
  53. Riethmüller G, Schneider-Gädicke E, Schlimok G, Schmiegel W. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes’C colorectal carcinoma. Lancet. 1994;343:1777–1783
  54. Riethmüller G, Holz E, Schlimok G, Schmiegel W, Raab R, Höffken K, et al. Monoclonal antibody therapy for resected Dukes’C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol. 1998;16:1788–1794
  55. Schlimok G, Pantel K, Loibner H, Fackler-Schwalbe I, Riethmüller G. Reduction of metastatic carcinoma cells in bone marrow by intravenously administered monoclonal antibody: Towards a novel surrogate test to monitor adjuvant therapies of solid tumours. Eur J Cancer. 1995;31:1799–1803
  56. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med. 1998;339:357–363
  57. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hemopoietic rescue as primary treatment for metastatic breast cancer. J Clin Oncol. 1995;13:2483–2489
  58. Kennedy MJ. High dose chemotherapy of breast cancer: Is the question answered?. J Clin Oncol. 1995;13:2477–2479
  59. Rahman ZU, Frye DK, Buzdar AU, Smith TL, Asmar L, Champlin RE, et al. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol. 1997;15:3171–3177
  60. Cooper BW, Moss TJ, Ross AA, Ybanez J, Lazarus HM. Occult tumor contamination of hematopoietic stem-cell products does not affect clinical outcome of autologous transplantation in patients with metastatic breast cancer. J Clin Oncol. 1998;16:3509–3517
  61. Franklin WA, Shpall EJ, Archer P, Johnston CS, Garza-Wiliams S, Hami L, et al. Immunocytochemical detection of breast cancer cells in marrow and peripheral blood of patients undergoing high dose chemotherapy with autologous stem cell support. Breast Cancer Res Treat. 1996;41:1–13
  62. Ross AA, Cooper BW, Lazarus HM, Mackay W, Moss TJ, Ciobanu N, et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. J Clin Oncol. 1993;9:2605–2610
  63. Tyer CL, Vredenburgh JJ, Heimer M, Peters WP, Bast RC. Breast cancer cells are effectively purged from peripheral blood progenitor cells with immunomagnetic techniques. Clin Cancer Res. 1996;2:81–86
  64. O’Briant KC, Shpall EJ, Houston LL, Peters WP, Bast RC. Elimination of clonogenic breast cancer cells from human bone marrow. Cancer. 1991;68:1272–1278
  65. Griwatz C, Brandt B, Assmann G, Zänker KS. An immunological enrichment method for epithelial cells from peripheral blood. J Immun Methods. 1995;183:251–265
  66. Naume B, Borgen E, Beiske K, Herstad TK, Ravnas G, Renolen A, et al. Immunomagnetic Techniques for the enrichment and detection of isolated breast carcinoma cells in bone marrow and peripheral blood. J Hematoth. 1997;6:103–114
  67. Ross AA. Minimal residual disease in solid tumor malignancies: a review. J Hematoth. 1998;7:9–18
  68. Johnson PWM, Burchill SA, Selby PJ. The molecular detection of circulating tumor cells. Br J Cancer. 1997;72:268–276
  69. Zippelius A, Kufer P, Honold G, Köllermann MW, Oberneder R, Schlimok G, et al. Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow. J Clin Oncol. 1997;15:2701–2708
  70. Ghossein RA, Rosai J. Polymerase chain reaction in the detection of micrometastases and circulating tumor cells. Cancer. 1996;78:10–16
  71. Slade MJ, Smith BM, Sinnett HD, Cross NCP, Coombes RC. Quantitative polymerase chain reaction for the detection of micrometastases in patients with breast cancer. J Clin Oncol. 1999;17:870–879
  72. Traweek ST, Liu J, Battifora H. Keratin gene expression in non epithelial tissues. Detection with polymerase chain reaction. Am J Pathol. 1993;142:1111–1118
  73. Schoenfeld A, Luqmani Y, Sinnett HD. Keratin 19 mRNA measurements to detect micrometastases in lymph nodes in breast cancer patients. Cancer Res. 1994;76:1639–1642
  74. Neumaier M, Gerhard M, Wagener C. Diagnosis of micrometastases by the amplification of tissue-specific genes. Gene. 1995;159:43–47
  75. Gunn J, McCall JL, Yun K, Wright PA. Detection of micrometastases in colorectal cancer patients by K19 and K20 reverse-transcription polymerase chain reaction. Lab Invest. 1996;75:611–616
  76. Noguchi S, Aihara T, Motomura K, Inaji H, Koyama H. Detection of breast cancer micrometastases in lymph nodes by amplification of keratin 19 mRNA with reverse-transcriptase polymerase chain reaction. Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]. 1996;23:50–55
  77. Noguchi S, Aihara T, Motomura K, Inaji H, Imaoka S, Koyama H. Detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptase and polymerase chain reaction. Comparison between MUC1 mRNA and keratin 19 mRNA amplification. Am J Path. 1996;148:649–656
  78. Castells A, Boix L, Bessa X, Gargallo L, Pique JM. Detection of colonic cells in peripheral blood of colorectal cancer patients by means of reverse transcriptase and polymerase chain reaction. Br J Cancer. 1998;78:1368–1372
  79. Mori M, Koshi M, Ueo H. Molecular detection of circulating solid carcinoma cells in the peripheral blood. Int J Cancer. 1996;68:739–743
  80. Wood DP, Banerjee M. Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival. J Clin Oncol. 1997;15:3451–3457
  81. Bostick PJ, Hoon DS, Cote RJ. Detection of carcinoembryonic antigen messenger RNA in lymph nodes from patients with colorectal cancer [letter]. N Engl J Med. 1998;339:1643–1644
  82. Bostick PJ, Chatterjee S, Chi D, Huynh K, Giuliano AE, Cote RJ, et al. Limitations of specific RT-PCR markers in the detection of metastases in the lymph nodes and blood of breast cancer patients. J Clin Oncol. 1998;16:2632–2640
  83. Hoon DS, Wang Y, Dale PS, Conrad AJ, Schmid P, Garrison D, et al. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol. 1995;13:2109–2116
  84. Gerhard M, Juhl H, Kalthoff H, Schreiber HW, Wagener C, Neumaier M. Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction. J Clin Oncol. 1994;12:725–729
  85. Datta YH, Adams PT, Ethier SP, Terry VH, Roth MS. Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J Clin Oncol. 1994;12:475–482
  86. Brown DC, Purushotham AD, Birnie GD, George WD. Detection of intraoperative tumor cell dissemination in patients with breast cancer by use of reverse transcription and polymerase chain reaction. Surgery. 1995;117:96–101
  87. Moscinski LC, Trudeau WL, Fields KK, Elfenbein GJ. High-sensitivity detection of minimal residual breast carcinoma using the polymerase chain reaction and primers for cytokeratin 19. Diagn Mol Pathol. 1996;5:173–180
  88. Fields KK, Elfenbein GJ, Trudeau WL, Perkins JB, Janssen WE, Moscinski LC. Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. J Clin Oncol. 1996;14:1868–1876
  89. LeMaire V, Sales JP, Wind P, Dumas F, Landi B, Fayemendy L, et al. Evaluation and interest in new molecular markers in colon cancer. Annales Pharmaceutiques Francaises. 1998;56:9–17
  90. Cote RJ, Peterson HF, Chaiwun B, Gelber RD, Goldhirsch A, Castiglione-Gerstch M, et al. The role of immunohistochemical detection of lymph node metastases in the management of breast cancer. Lancet. 1999;354:896–900
  91. Gusterson BA, Ott R. Occult axillary lymph node micrometastasis in breast cancer. Lancet. 1990;336:434–435
  92. Neville AM. Breast cancer micrometastases in lymph nodes and bone marrow are prognostically important. Ann Oncol. 1991;2:13–14
  93. Fisher ER, Swamidoss S, Lee CH, Rockette H, Redmond C, Fisher B. Detection and significant of occult axillary node metastases in patients with invasive breast cancer. Cancer. 1978;42:2025–2031
  94. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220:391–398
  95. Giuliano AE, Dale PS, Turner RR, Morton DL, Evans SW, Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg. 1995;222:394–399
  96. Galasko, C. S. B. Skeletal Metastases, Butterworths, London, 1986
  97. Diel, I. J. Kaufmann, M. Bastert, G. Metastatic Bone Disease, Springer, Berlin, Heidelberg, New York, 1994
  98. Pantel K, Schlimok G, Braun S, Kutter D, Lindemann F, Schaller G, et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst. 1993;85:1419–1424
  99. Putz E, Witter K, Offner S, Stosiek P, Zippelius A, Johnson J, et al. Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: establishment of working models for human micrometastases. Cancer Res. 1999;59:241–248
  100. Solomayer EF, Diel IJ, Wallwiener D, Bode S, Meyberg G, Sillem M, et al. Prognostic relevance of urokinase plasminogen activator detection in micrometastatic cells in the bone marrow of patients with primary breast cancer. Br J Oncol. 1997;76:812–818
  101. Solomayer EF, Diel IJ, Meyberg GC, Gollan Ch, Bode S, Wallwiener D, et al. Prognostic relevance of cathepsin D detection in micrometastatic cells in the bone marrow of patients with primary breast cancer. Breast Cancer Res Treat. 1998;49:145–154
  102. Porro G, Ménard S, Tagliabue E, Orefice S, Salvadori B, Squicciarini P, et al. Monoclonal antibody detection of carcinoma cells in bone marrow biopsy specimens from breast cancer. Cancer. 1988;61:2407–2411
  103. Untch M, Harbeck N, Eiermann W. Micrometastases in bone marrow in patients with breast cancer. Br Med J. 1988;296:290
  104. Salvadori B, Squicciarini B, Rovini D, Orefice S, Andreola S, Rilke F, et al. Use of monoclonal antibody Mbr1 to detect micrometastases in bone marrow specimens of breast cancer patients. Eur J Cancer. 1990;26:865–867
  105. Cote RJ, Rosen PP, Lesser ML, Old LJ, Osborne MP. J Clin Oncol. 1991;9:1749–1756
  106. Harbeck N, Untch M, Pache L, Eiermann W. Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up. Br J Cancer. 1994;69:566–571
  107. Merkle E, Bähr J, Henke A, Bühner M, Martus P. Immunzytochemischer Nachweis von Tumorzellen im Knochenmark als Prognosefaktor beim Mammakarzinom. Geburtsh u Frauenheilk. 1994;54:662–669
  108. Molino A, Pelosi G, Turazza M, Sperotto L, Bonetti A, Nortilli R, et al. Bone marrow micrometastases in 109 breast cancer patients: Correlations with clinical and pathological features and prognosis. Breast Cancer Res Treat. 1997;42:23–30

PII: S0305-7372(99)90150-0

doi: 10.1053/ctrv.1999.0150

Cancer Treatment Reviews
Volume 26, Issue 1 , Pages 53-65 , February 2000

Article Tools